source
- Merck halts $2.7 billion BTK inhibitor program after negative phase 3 dataMerck announced it is discontinuing its BTK inhibitor nemtabrutinib program, ending three phase 3 trials in chronic lymphocytic leukemia and small lymphocytic lymphoma. The decision follows a reco…
- Medtronic to acquire Contego Medical for over $380 million to expand carotid and peripheral vascular portfolioMedtronic announced it will purchase Contego Medical, a developer of carotid artery disease and peripheral thrombectomy technologies. The deal is valued at more than $380 million, with potential a…